{"version":"1.0","type":"link","title":"Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer: insights from a large cohort in central south China.","author_name":"Wu J 외","author_url":"https://prs-insight.online/author/Wu%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/90001","thumbnail_width":1200,"thumbnail_height":630}